KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Regeneron Pharmaceuticals (REGN) Operating Expenses (2016 - 2025)

Regeneron Pharmaceuticals (REGN) has 17 years of Operating Expenses data on record, last reported at $3.0 billion in Q4 2025.

  • For Q4 2025, Operating Expenses rose 7.34% year-over-year to $3.0 billion; the TTM value through Dec 2025 reached $10.8 billion, up 5.42%, while the annual FY2025 figure was $10.8 billion, 5.42% up from the prior year.
  • Operating Expenses reached $3.0 billion in Q4 2025 per REGN's latest filing, up from $2.7 billion in the prior quarter.
  • Across five years, Operating Expenses topped out at $3.0 billion in Q4 2025 and bottomed at $1.3 billion in Q2 2022.
  • Average Operating Expenses over 5 years is $2.3 billion, with a median of $2.4 billion recorded in 2024.
  • Peak YoY movement for Operating Expenses: decreased 29.07% in 2022, then skyrocketed 68.55% in 2023.
  • A 5-year view of Operating Expenses shows it stood at $1.8 billion in 2021, then surged by 46.32% to $2.6 billion in 2022, then dropped by 6.09% to $2.5 billion in 2023, then increased by 13.72% to $2.8 billion in 2024, then rose by 7.34% to $3.0 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Expenses were $3.0 billion in Q4 2025, $2.7 billion in Q3 2025, and $2.6 billion in Q2 2025.